1. Home
  2. ADPT vs WRBY Comparison

ADPT vs WRBY Comparison

Compare ADPT & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.56

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Warby Parker Inc.

WRBY

Warby Parker Inc.

HOLD

Current Price

$28.90

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
WRBY
Founded
2009
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ADPT
WRBY
Price
$13.56
$28.90
Analyst Decision
Strong Buy
Buy
Analyst Count
9
11
Target Price
$17.78
$27.10
AVG Volume (30 Days)
1.6M
2.5M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
105.88
EPS
N/A
0.03
Revenue
$276,976,000.00
$871,905,000.00
Revenue This Year
$3.98
$14.48
Revenue Next Year
$22.72
$16.41
P/E Ratio
N/A
$984.00
Revenue Growth
54.77
13.04
52 Week Low
$8.50
$14.96
52 Week High
$20.76
$31.00

Technical Indicators

Market Signals
Indicator
ADPT
WRBY
Relative Strength Index (RSI) 45.10 66.97
Support Level $12.22 $21.22
Resistance Level $15.38 $31.00
Average True Range (ATR) 0.79 1.77
MACD -0.02 0.71
Stochastic Oscillator 27.88 88.78

Price Performance

Historical Comparison
ADPT
WRBY

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About WRBY Warby Parker Inc.

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Share on Social Networks: